The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation
Mirabegron, a selective β3-adrenoreceptor agonist, is a well-established alternative to antimuscarinics in adults with overactive bladder (OAB) symptoms and is under development for use in pediatric patients. Understanding drug pharmacokinetics (PK) in pediatric patients is needed to determine appropriate dosing. Conducti ng these studies is ethically complex, particularly as regulatory guidance requires that PK is assessed in pediatric patients with a therapeutic need for the drug. It is also vital to evaluate the safety/tolerability and palatability/acceptability of pediatric formulations.
Source: Journal of Pediatric Urology - Category: Urology & Nephrology Authors: S øren Rittig, Małgorzata Baka-Ostrowska, Camilla Tøndel, Johan Vande Walle, Birgitta Kjaeer, Paul Passier, Brigitte Bosman, Otto Stroosma, Stacey Tannenbaum Source Type: research
More News: Brain | Child Development | Children | Medical Ethics | Neurology | Overactive Bladder | Overactive Bladder Syndrome | Pediatrics | Study | Urology & Nephrology